From January 13 to 16, 2025, the 43rd J.P. Morgan Healthcare Conference will be held in San Francisco, USA.The conference brought together the world's top biotechnology companies, pharmaceutical companies, medical device companies, investors, and numerous industry leaders.One of the most influential annual events in the global healthcare field.Known as"Global Development and Investment Trends in the Pharmaceutical and Healthcare Sector"”。
The 2025 Conference Focuses onM&A Boom Returns, R&D Focuses on DifferentiationWait for the lineIndustry trends, at the same time,The Rise of Chinese Corporate PowerWorthy of attention. Below is a summary of the highlights, corporate developments, and industry trends from this year's conference compiled by Siyu for readers' reference.
# Medical Device Giants' Layout
Johnson & JohnsonCEO Joaquin Duato stated,Johnson & Johnson's current medical business includes50%Sales are driven by high-growth markets, and by 2027, one-third of revenue is expected to come from new products.VARIPULSE Suspended in the U.S.:Johnson & Johnson's first PFA product, VARIPULSE, has paused external evaluation and commercial application in the United States. This is due to the discovery of some neurovascular side effects during the limited market release in the U.S.Out of extreme caution, it was decided to halt external assessments to ensure proper configuration.
Outside the United States, VARIPULSE continues to be commercialized, and the company is working to identify the root cause so that VARIPULSE can re-enter the external evaluation phase in the United States.Surgical Robotics Field:On June 7, 2024, Johnson & Johnson announced that DePuy Synthes has received 510(k) clearance from the FDA.InUnicompartmental Knee Arthroplasty (UKA)Application of VELYS™ Robotic-Assisted Solution in China。November 2024On the 12th, Johnson & Johnson announced that the U.S. FDA had approvedItsOttava Surgical Robot Investigational Device Exemption (IDE) Application. At present,Johnson & Johnson is actively preparing the site to recruit patients and begin clinical trials for surgical cases.Atrial Fibrillation Treatment Field:On January 10, 2025, Johnson & Johnson announced its Dual Energy ThermoCool SmartTouch™ SF catheter.Has obtained European CE certification, used to treat arrhythmias such as atrial fibrillation.Dual Energy ThermoCool SmartTouch™ SF CatheterField of Heart Failure Treatment:Johnson & JohnsonDedicated to the research and development of cardiac pumps and atrial shunt devices. For atrial fibrillation, the company has developed a complete ablation treatment solution and is actively promoting left atrial appendage closure technology.M&A Expansion:Johnson & Johnson has built a strong cardiovascular product portfolio through a series of strategic investments, acquiring companies such as Abiomed, Shockwave, V-Wave, and Laminar. Johnson & Johnson expressed satisfaction with the outcomes of acquiring Abiomed and Shockwave, as both companies have performed in line with market expectations.Boston Scientific predicts that by 2026, more than 60% of global atrial fibrillation (AFib) procedures will utilize PFA technology.Currently, Abbott, the competitor, has not yet obtained relevant approval. Johnson & Johnson suspended the use of its VARIPULSE device in the United States last week, while Medtronic has become Boston Scientific's direct competitor in the PFA field.In the field of cardiac electrophysiology (EP), Boston Scientific originally ranked fourth globally. The company anticipates moving up to the second position worldwide by the middle of 2025 and aims to become the global leader in this field within the next few years.Mike Mahoney, CEO of the company, stated that Boston Scientific's 2025 PFA growth plan includesDilationFurther penetrate the Chinese and Japanese markets, expand into the U.S. and European markets, and increase the use of its mapping systems.Clinical data and indication expansion are also crucial for achieving long-term business growth.Last year, a trial funded by Boston Scientific found that performing left atrial appendage closure (LAAC) during ablation reduced the risk of bleeding compared to the use of blood thinners.Boston Scientific's Watchman device holds a significant share in the U.S. LAAC market, and an expansion of the Watchman indications is anticipated in the second half of this year to include use in patients post-ablation.
Medtronic
Medtronic CEO Geoff Martha told investors that the company's core businesses, including cardiac rhythm management, spinal and transcatheter heart valve businesses, were all showing good growth momentum.
Cardiac Ablation Business:The company expects new products soonThe Four Fastest-Growing FieldsYesCardiac ablation, renal denervation, neuromodulation, and automated insulin delivery systems for diabetes management。Cardiac AblationThe scale of the market is expected to reach$90 billionMedtronic's related business is expected to achieve strong double-digit growth in the third fiscal quarter.Currently, the company's PulseSelect PFA catheter is expanding its production scale.Neuromodulation Business:Invest in sensing technologies for the brain and nervous system.Medtronic's Adaptive Deep Brain Stimulation (DBS) Technology Receives European CE Mark — The World’s First Fully Closed-Loop DBS System Offering Self-Adjusting Brain Stimulation for Parkinson’s Patients. Submissions to the U.S. FDA are currently being prepared.Diabetes Business:Has already turned a profit and is growing at a double-digit rate,Simplera Continuous Glucose Monitoring SensorWith dimensions only half the size of previous sensors, it is more convenient to use and is driving growth in the international market.Renal Denervation:United StatesThe Centers for Medicare and Medicaid Services has decided to conduct renal denervationAnalysis of Health Insurance Coverage in China, Medtronic'sSymplicity Spyral DeviceProgress has been made in medical insurance and payment, preparing for the vast hypertension market.Currently, the global hypertension market penetration rate is only 1%, representing a market opportunity worth $1 billion.
Following a major company-wide reorganization, Baxter International revealed to investors at the J.P. Morgan Healthcare Conference that more changes are in the works. These changes includeAsset divestitures, small-scale acquisitions, and evaluation of product supply in specific regions.In August 2024, Baxter and Carlyle Group announced that they had signed a definitive agreement, under which Carlyle Group will$3.8 BillionAcquisition of Vantive, Baxter's Renal Care Subsidiary.According to the terms of the final agreement, after certain transaction completion adjustments, Baxter is expected to receive approximately $3.5 billion.The transaction is expected to be completed in early 2025.# Pharmaceutical Giants' Layout- International Enterprises
Johnson & Johnson:Taking the lead, Johnson & Johnson splashes $14.6 billion to acquire Intra-Cellular Therapies,Lilly, GSK, AbbVieFollowing that, they invested billions of dollars heavily betting on PI3Kα inhibitors, KIT tyrosine kinase inhibitors, and tri-specific antibodies.Lilly:During the conference, Eli Lilly and Company announced$1 billionCash acquisition of Scorpion's PI3Kα inhibitor project STX-478, with a commitment to add $1.5 billion after the project passes regulatory approval and achieves sales milestones.AbbVie:AbbVie and Simcere Pharmaceutical Group Co., Ltd. SubsidiarySimcere ZaimingAnnounce that the two parties have reached a license option agreement for the candidate drug SIM0500 under development., with potential milestone payments up to1.05 billionDollar。
SIM0500 is currently being developed in both China and the United States for the treatment of relapsed or refractory multiple myeloma.Phase 1 Clinical Study of (MM).
GSK：GSK announced that it will invest$1.15 billionThe acquisition of IDRx's lead candidate drug IDRX-42 is similar to GSK's previous acquisition of BELLUS Health to obtain a treatment for refractory chronic cough.
Pro Pharma:Hengdian Group Holding's investment and corporate development departments, as well as ProPharm, attended the meeting to strengthen international cooperation and influence through participation.
Pharmaceuticals in China（BioToChina. org）：The first organization connecting China with global pharmaceuticals, biotechnology, and medical device business development (BD). Its core platformACCESS CHINAIt is an efficient deal-facilitating platform, aimed at helping Western pharmaceutical and biotechnology leaders enter or expand in the Chinese market.During JPM25, the "ACCESS CHINA Biotech Forum" was held, connecting biotechnology companies in China and abroad to promote collaboration and investment.
BeiGene:BeiGene CEO John Oyler introduced the recent business status and the company'sHematological TumorAndSolid TumorThe pipeline layout in the field, as well as future development plans and expected progress, while mentioning that a full-year operating profit for 2025 is expected to be positive.After the news spread, the stock price continued to rise, once increasing by nearly10%。At the close, BeiGene's A-share was trading at 178.6 yuan per share, up9.44%, with a current market value of247.4 billion yuan。
In addition, there are alsoZai Lab, Legend Biotech, 3SBio, Akeso Biopharma, Innovent Biologics, Junshi Biosciences, WuXi Biologics, WuXi XDC, Tigermed, GenScript Biotech, etc.Dozens of companies attended the meeting.Moreover, an increasing number of U.S. companies are importing drugs from China, a trend that highlights the industry's recognition of China's innovative capabilities despite complex geopolitical dynamics.
Johnson & Johnson Kicks Off 2025 Pharma M&A Frenzy with $14.6B Acquisition of Intra-Cellular. Amid patent cliffs and intensifying market competition, mergers and acquisitions along with integration remainLikeLilly, GSK, AbbVieAn Important Means for Industry Giants to Achieve Growth。Related Reading:Over 100 Billion! Johnson & Johnson's Mega Acquisition at the Start of 2025!
The pharmaceutical industry has long faced issues of patent expiration and intensifying market competition. Patent expiration means that some of a company’s key drugs will face competition from generics, leading to a sharp decline in revenue. To address this challenge, pharmaceutical companies often expand their product lines and enhance market competitiveness through mergers, acquisitions, and integration.
Companies are paying more attention to finding breakthroughs in crowded markets through differentiation strategies. Pfizer has adopted a differentiation strategy in the obesity treatment field, focusing heavily on small-molecule GLP-1R drugs. Currently, Pfizer has advanced multiple candidate drugs to the clinical stage.
At this conference, NVIDIA announced partnerships with IQVIA, Illumina, Mayo Clinic, and Arc Institute.
Mayo Clinic Utilizes Nvidia's Technology to Accelerate the Development of Next-Generation Pathology Foundation Models, with Its Digital Pathology Platform Featuring a Unique Dataset to Support the Creation of Foundation Models.
Clinical research service provider IQVIA is using NVIDIA AI Foundry services to build custom foundational models and develop proxy AI solutions to accelerate research, clinical development, and access to new therapies.
Illumina, a DNA sequencing and informatics technology company, is integrating accelerated computing and AI toolsets into its multi-omics analysis software and workflows to help researchers, pharmaceutical companies, and other life science customers more easily access analysis and insights into the human genome.
Arc Institute is collaborating with NVIDIA to develop and share powerful AI models and tools to advance biomedical discoveries.
# Conclusion
The JPM25 Conference, as the annual event of the global healthcare industry, is undoubtedly of great importance. It serves not only as a platform for companies to showcase their latest achievements but also as a weathervane for industry trends.
The 2025 conference witnessed Johnson & Johnson's acquisition of Intra-Cellular Therapies for $14.6 billion, a blockbuster deal that injected a strong boost into the industry's recovery. In addition, the conference also focused on PFA technology in the field of cardiac electrophysiology, becoming a hot topic of discussion.
Looking ahead, the medical industry will continue to dance with opportunities through innovative breakthroughs, with digital transformation and precision medicine becoming the key drivers of development.
# List of Award-Winning Medical Device Companies
Global Surgical Robotics Industry Awards 2024
Global Medical Technology Innovation Award 2024
Global MedTech Newcomer Award 2024
Global Innovation Medical Device Award 2024
# Overseas Large Medical Device Manufacturers
#EnChina's Major Medical Device ManufacturersMindray Medical｜Lepu Medical|MicroPort｜Weigao Group|United Imaging Healthcare
